Introduction to Prion Disorders

Neurodegeneration: The Molecular Pathology of Dementia and Movement Disorders: Second Edition

Volumn , Issue , 2011, Pages 313-321

  Aguzzi, Adriano ^a   Kana, Veronika ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Amyloid; Prion; Prion diseases; Prion protein; Protein aggregation; Protein only hypothesis; Transmissible spongiform encephalopathy

Indexed keywords

EID: 84886029700     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444341256.ch31     Document Type: Chapter

References (56)

1. Aguzzi A, Polymenidou M. Mammalian prion biology: one century of evolving concepts. Cell 2004; 116: 313-327.
2. Griffith J. Self-replication and scrapie. Nature 1967; 215: 1043-1044.
3. Bolton D, McKinley M, Prusiner S. Identification of a protein that purifies with the scrapie prion. Science 1982; 218: 1309-1311.
4. Prusiner S. Novel proteinaceous infectious particles cause scrapie. Science 1982; 216: 136-144.
5. Chesebro B, Race R, Wehrly K, et al. Identification of scrapie prion protein-specific mRNA in scrapie-infected and uninfected brain. Nature 1985; 315: 331-3333.
6. Oesch B, Westaway D, Wälchli M, et al. A cellular gene encodes scrapie PrP 27-30 protein. Cell 1985; 40: 735-746.
7. Büeler H, Fischer M, Lang Y, et al. Normal development and behaviour of mice lacking the neuronal cell-surface PrP protein. Nature 1992; 356: 577-582.
8. Büeler H, Aguzzi A, Sailer A, et al. Mice devoid of PrP are resistant to scrapie. Cell 1993; 73: 1339-1347.
9. Legname G, Baskakov I, Nguyen, et al. Synthetic mammalian prions. Science 2004; 305: 673-676.
10. Makarava N, Kovacs G, Bocharova O, et al. Recombinant prion protein induces a new transmissible prion disease in wild-type animals. Acta Neuropathol 2010; 119: 177-187.
11. Kim J, Cali I, Surewicz K, et al. Mammalian prions generated from bacterially expressed prion protein in the absence of any mammalian cofactors. J Biol Chem 2010; 285: 14083-14087.
12. Deleault N, Harris B, Rees J, Supattapone S. Formation of native prions from minimal components in vitro. Proc Natl Acad Sci USA 2007; 104: 9741-9746.
13. Wang F, Wang X, Yuan C, Ma J. Generating a prion with bacterially expressed recombinant prion protein. Science 2010; 327: 1132-1135.
14. Supattapone S. Biochemistry. What makes a prion infectious? Science 2010; 327: 1091-1092.
15. Li J, Browning S, Mahal S, Oelschlegel A, Weissmann C. Darwinian evolution of prions in cell culture. Science 2010; 327: 869-872.
16. Aguzzi A, Heikenwalder M, Polymenidou M. Insights into prion strains and neurotoxicity. Nat Rev Mol Cell Biol 2007; 8: 552-561.
17. Aguzzi A, Baumann F, Bremer J. The prion's elusive reason for being. Annu Rev Neurosci 2008; 31: 439-477.
18. Linden R, Martins V, Prado M, Cammarota M, Izquierdo I, Brentani R. Physiology of the prion protein. Physiol Rev 2008; 88: 673-728.
19. Bremer J, Baumann F, Tiberi C, et al. Axonal prion protein is required for peripheral myelin maintenance. Nat Neurosci 2010; 13: 310-318.
20. Laurén J, Gimbel D, Nygaard H, Gilbert J, Strittmatter S. Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature 2009; 457: 1128-1132.
21. Aguzzi A, O'Connor T. Protein aggregation diseases: pathogenicity and therapeutic perspectives. Nat Rev Drug Discov 2010; 9: 237-248.
22. Glatzel M, Stoeck K, Seeger H, Lührs T, Aguzzi A. Human prion diseases: molecular and clinical aspects. Arch Neurol 2005; 62: 545-552.
23. Hsiao K, Prusiner S. Inherited human prion diseases. Neurology 1990; 40: 1820-1827.
24. Glatzel M, Abela E, Maissen M, Aguzzi A. Extraneural pathologic prion protein in sporadic Creutzfeldt-Jakob disease. N Engl J Med 2003; 349: 1812-1820.
25. Bruce M, McConnell I, Will R, Ironside J. Detection of variant Creutzfeldt-Jakob disease infectivity in extraneural tissues. Lancet 2001; 358: 208-209.
26. Aguzzi A, Heikenwalder M. Pathogenesis of prion diseases: current status and future outlook. Nat Rev Microbiol 2006; 4: 765-775.
27. Klein M, Frigg R, Flechsig E, et al. A crucial role for B cells in neuroinvasive scrapie. Nature 1997; 390: 687-690.
28. Klein M, Kaeser P, Schwarz P, et al. Complement facilitates early prion pathogenesis. Nat Med 2001; 7: 488-492.
29. Prinz M, Heikenwalder M, Junt T, et al. Positioning of follicular dendritic cells within the spleen controls prion neuroinvasion. Nature 2003; 425: 957-662.
30. Prinz M, Montrasio F, Klein M, et al. Lymph nodal prion replication and neuroinvasion in mice devoid of follicular dendritic cells. Proc Natl Acad Sci USA 2002; 99: 919-924.
31. Heikenwalder M, Federeau C, Boehmer L, et al. Germinal center B cells are dispensable in prion transport and neuroinvasion. J Neuroimmunol 2007; 192: 113-123.
32. Glatzel M, Heppner F, Albers K, Aguzzi A. Sympathetic innervation of lymphoreticular organs is rate limiting for prion neuroinvasion. Neuron 2001; 31: 25-34.
33. Aguzzi A, Heikenwalder M. Prions, cytokines, and chemokines: a meeting in lymphoid organs. Immunity 2005; 22: 145-154.
34. Bremer J, Heikenwalder M, Haybaeck J, et al. Repetitive immunization enhances the susceptibility of mice to peripherally administered prions. PLoS One 2009; 4: e7160.
35. Seeger H, Heikenwalder N, Zeller N, et al. Coincident scrapie infection and nephritis lead to urinary prion excretion. Science 2005; 310: 324-326.
36. Ligios C, Sigurdson C, Santucciu C, et al. PrPSc in mammary glands of sheep affected by scrapie and mastitis. Nat Med 2005; 11: 1137-1138.
37. Heikenwalder M, Zeller N, Seeger H, et al. Chronic lymphocytic inflammation specifies the organ tropism of prions. Science 2005; 307: 1107-1110.
38. Prinz M, Heikenwalder M, Schwarz P, Takeda K, Akira S, Aguzzi A. Prion pathogenesis in the absence of Toll-like receptor signalling. EMBO Rep 2003; 4: 195-199.
39. Heppner F, Greter M, Marino D, et al. Experimental autoimmune encephalomyelitis repressed by microglial paralysis. Nat Med 2005; 11: 146-152.
40. Falsig J, Aguzzi A. The prion organotypic slice culture assay-POSCA. Nat Protoc 2008; 3: 555-562.
41. Aguzzi A, Sigurdson C. Antiprion immunotherapy: to suppress or to stimulate? Nat Rev Immunol 2004; 4: 725-736.
42. Montrasio F, Frigg R, Glatzel M, et al. Impaired prion replication in spleens of mice lacking functional follicular dendritic cells. Science 2000; 288: 1257-1259.
43. Mabbott N, Young J, McConnell I, Bruce M. Follicular dendritic cell dedifferentiation by treatment with an inhibitor of the lymphotoxin pathway dramatically reduces scrapie susceptibility. J Virol 2003; 77: 6845-6854.
44. Horiuchi M, Caughey B. Specific binding of normal prion protein to the scrapie form via a localized domain initiates its conversion to the protease-resistant state. EMBO J 1999; 18: 3193-3203.
45. Gabizon R, McKinley M, Groth D, Prusiner S. Immunoaffinity purifi-cation and neutralization of scrapie prion infectivity. Proc Natl Acad Sci USA 1988; 85: 6617-6621.
46. Peretz D, Williamson A, Kaneko K, et al. Antibodies inhibit prion propagation and clear cell cultures of prion infectivity. Nature 2001; 412: 739-743.
47. Brandner S, Isenmann S, Raeber A, et al. Normal host prion protein necessary for scrapie-induced neurotoxicity. Nature 1996; 379: 339-343.
48. Prusiner S, Groth D, Serban A, et al. Ablation of the prion protein (PrP) gene in mice prevents scrapie and facilitates production of anti-PrP antibodies. Proc Natl Acad Sci USA 1993; 90: 10608-10612.
49. Heppner F, Musahl C, Arrighi I, et al. Prevention of scrapie pathogenesis by transgenic expression of anti-prion protein antibodies. Science 2001; 294: 178-182.
50. Doh-Ura K, Iwaki T, Caughey B. Lysosomotropic agents and cysteine protease inhibitors inhibit scrapie-associated prion protein accumulation. J Virol 2000; 74: 4894-4897.
51. Farquhar C, Dickinson A, Bruce M. Prophylactic potential of pentosan polysulphate in transmissible spongiform encephalopathies. Lancet 1999; 353: 117.
52. Trevitt C, Collinge J. A systematic review of prion therapeutics in experimental models. Brain 2006; 129: 2241-2265.
53. Caughey B, Race R. Potent inhibition of scrapie-associated PrP accumulation by congo red. J Neurochem 1992; 59: 768-771.
54. Collinge J, Gorham M, Hudson F, et al. Safety and efficacy of quinacrine in human prion disease (PRION-1 study): a patient-preference trial. Lancet Neurol 2009; 8: 334-344.
55. Aguzzi A, Rajendran L. The transcellular spread of cytosolic amyloids, prions, and prionoids. Neuron 2009; 64: 783-790.
56. Brundin P, Melki R, Kopito R. Prion-like transmission of protein aggregates in neurodegenerative diseases. Nat Rev Mol Cell Biol 2010; 11: 301-307.